These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 5128330)

  • 1. Insulin treatment does not induce glucagon antibodies.
    Thomsen HG
    Horm Metab Res; 1971 Jan; 3(1):57-8. PubMed ID: 5128330
    [No Abstract]   [Full Text] [Related]  

  • 2. Insulin binding and free insulin in serum of insulin-treated diabetics.
    Lev-Ran A; Ratt L
    Horm Metab Res; 1973 Mar; 5(2):67-70. PubMed ID: 4707702
    [No Abstract]   [Full Text] [Related]  

  • 3. [Experiences in the treatment of diabetes with insulins of monocomponent (MC) and monospecies (MS) type].
    Andreani D; Iavicoli M; Colletti A; Menzinger G
    Folia Endocrinol; 1972 Dec; 25(6):516-39. PubMed ID: 4581824
    [No Abstract]   [Full Text] [Related]  

  • 4. Insulin antibody formation during long-term treatment with monocomponent and monospecies insulin.
    Piers DA; Sluiter WJ; Reitsma WD; Doorenbos H
    Neth J Med; 1974; 17(4-5):234-8. PubMed ID: 4465730
    [No Abstract]   [Full Text] [Related]  

  • 5. [KH metabolic pattern and insulin antibody level during treatment of diabetes mellitus with conventional and/or prepurified insulin preparations].
    Göbel P; Kramer W; Heni F
    Verh Dtsch Ges Inn Med; 1977 Apr 17-21; 83():1426-9. PubMed ID: 611859
    [No Abstract]   [Full Text] [Related]  

  • 6. [Proceedings: 2 years of experiences with monocomponent insulin in diabetic patients].
    Fankhauser S; Michl J; Morell B
    Helv Med Acta; 1974 May; 37(5-6):365-6. PubMed ID: 4605883
    [No Abstract]   [Full Text] [Related]  

  • 7. The insulins.
    Bressler R; Galloway JA
    Ration Drug Ther; 1971 May; 5(5):1-6. PubMed ID: 5162936
    [No Abstract]   [Full Text] [Related]  

  • 8. [Serum levels of insulin-binding antibodies treated with monocomponent insulin].
    Czyzyk A; Lawecki J; Rogala H; Miedzińska E; Popik-Hankiewicz A
    Pol Tyg Lek; 1974 Feb; 29(8):301-4. PubMed ID: 4856084
    [No Abstract]   [Full Text] [Related]  

  • 9. Glucagon antibodies after long-term insulin treatment in a diabetic child.
    Stahl M; Nars PW; Herz G; Baumann JB; Girard J
    Horm Metab Res; 1972 May; 4(3):224-5. PubMed ID: 5065152
    [No Abstract]   [Full Text] [Related]  

  • 10. [Is proinsulin contamination of commercial insulin preparations responsible for the stimulation of insulin antibodies?].
    Kerp L; Steinhilber S; Kasemir H
    Klin Wochenschr; 1970 Jul; 48(14):884-5. PubMed ID: 5535446
    [No Abstract]   [Full Text] [Related]  

  • 11. [Possibilities of therapy with various insulin preparations].
    Rabast R; Schönborn J
    Med Klin; 1976 Jun; 71(24):1023-30. PubMed ID: 933999
    [No Abstract]   [Full Text] [Related]  

  • 12. [The insulin treatment and insulin-antigenicity].
    Fankhauser S
    Med Welt; 1975 Oct; 26(40):1831-3. PubMed ID: 1186476
    [No Abstract]   [Full Text] [Related]  

  • 13. [Insulin treatment of diabetes mellitus].
    Sala G
    Minerva Med; 1975 Nov; 66(79):4162-7. PubMed ID: 812026
    [No Abstract]   [Full Text] [Related]  

  • 14. The half-life of 131 I-insulin in different groups of patients compared with normal subjects.
    van Rooyen RJ; de Bruin EJ; Bieler EU; Hoog JM
    S Afr Med J; 1972 Dec; 46(49):1927-31. PubMed ID: 4631796
    [No Abstract]   [Full Text] [Related]  

  • 15. [Proinsulin and a-component antibodies in diabetics treated with monocomponent and conventional insulin].
    Gamba S; Barbero PL; Bollati C; Castellazzi R; D'Adda A; Bruni B
    Minerva Dietol Gastroenterol; 1979; 25(3):309-14. PubMed ID: 400003
    [No Abstract]   [Full Text] [Related]  

  • 16. The immunogenic properties of highly purified insulin preparations: The clinical importance of insulin-binding antibodies.
    Anderson OO
    Acta Endocrinol (Copenh); 1975 Apr; 78(4):723-35. PubMed ID: 1173962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insulin antibody production studied quantitatively with a modified radioimmunoassay technique and with radioimmunoelectrophoresis in patients treated with monocomponent (MC) insulin.
    Bruni B; Ricci C; Giolitti A; Osenda M; D'Alberto M; Turco GL
    J Nucl Biol Med; 1973; 17(3):123. PubMed ID: 4746315
    [No Abstract]   [Full Text] [Related]  

  • 18. Miscibility of short- and intermediate-acting insulins.
    Heine RJ
    Neth J Med; 1985; 28 Suppl 1():12-4. PubMed ID: 3892332
    [No Abstract]   [Full Text] [Related]  

  • 19. [Serum I-125 insulin IgG binding capacity in diabetic patients on a long-term insulin treatment, with reference to indications for monocomponent insulin therapy].
    Bruni B; Castellazzi R; Osenda M; Papotti G; Turco GL
    Minerva Med; 1974 Mar; 65(20):1071-7. PubMed ID: 4827592
    [No Abstract]   [Full Text] [Related]  

  • 20. [Clinical experiences with monocomponent insulins].
    Bruni Bocher K; Giolitti A; Turco GL; Benedetto P; Bruni B
    Minerva Med; 1975 Mar; 66(19):909-30. PubMed ID: 1124144
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.